Viswanathan Muthusamy
Affiliations: | 2008- | Yale University, New Haven, CT |
Google:
"Viswanathan Muthusamy"Mean distance: 8.42 | S | N | B | C | P |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Caianiello DF, Zhang M, Ray JD, et al. (2021) Bifunctional small molecules that mediate the degradation of extracellular proteins. Nature Chemical Biology |
| Jiang X, Muthusamy V, Fedorova O, et al. (2019) Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses. The Journal of Experimental Medicine |
| Chirkin E, Muthusamy V, Mann P, et al. (2017) Neutralization of pathogenic fungi with small-molecule immunotherapeutics. Angewandte Chemie (International Ed. in English) |
| Micevic G, Muthusamy V, Damsky W, et al. (2016) DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR. Cell Reports |
| Rullo AF, Fitzgerald KJ, Muthusamy V, et al. (2016) Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor. Angewandte Chemie (International Ed. in English) |
| Muthusamy V, Premi S, Soper C, et al. (2013) The hematopoietic stem cell regulatory gene latexin has tumor-suppressive properties in malignant melanoma. The Journal of Investigative Dermatology. 133: 1827-33 |
| Smalley KS, Contractor R, Nguyen TK, et al. (2008) Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Research. 68: 5743-52 |
| Muthusamy V, Duraisamy S, Bradbury CM, et al. (2006) Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Research. 66: 11187-93 |